Efficacy of Everolimus and Tolerability with Long-Term Use Abstract #568

Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Aim(s): To assess disease control rate (DCR) and progression-free survival (PFS) with respect to the number of prior treatment lines and evaluation of frequency and timeframe of pneumonitis.
Materials and methods: We analyzed 60 patients (pts) treated with Everolimus +/- Octreotide LAR 30 mg. Median follow-up was 15 months. Location of primary tumor (PT) was in the pancreas or ileum in 24 cases each (41%), respectively, followed by lung (9%, n=5) and others (CUP, rectum, stomach).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes
Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Rodrigo G Taboada
#1417 Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice
Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#1413 Everolimus (EVE) Treatment for Advanced G1-G2 Neuroendocrine Tumours (NETs) in the Community Setting: Clinical Benefit Irrespective of Previous Therapies
Introduction: Randomized studies have shown EVE has antitumour activity in advanced G1-G2 NETs. However, data outside regulatory trials are limited.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#1496 Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-differentiated Neuroendocrine Tumors Resistant to Prior Treatments
Introduction: Alternating treatment with sunitinib and everolimus, has been shown to be efficacious in renal cell carcinoma
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Angelousi
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard